小鼠骨髓瘤杂交细胞在动物体内的抗肿瘤保护作用

In Vivo Antitumor Protection of Hybrid Cell of Myeloma in Mice

将小鼠ＳＰ２／０骨髓瘤细胞与脂多糖（ＬＰＳ）活化的同系动物来源的Ｂ淋巴细胞融合，获得１Ｆ１１和２Ａ６杂交细胞。采用荷瘤小鼠模型，观察了１Ｆ１１、２Ａ６杂交细胞的免疫治疗对小鼠存活率、小鼠脾ＣＴＬ细胞体外杀瘤活性的影响。结果显示，腹腔荷骨髓瘤小鼠经ＳＰ２／０杂交细胞治疗后第３周时存活率均为５０．０％，对照组小鼠全部死亡；１Ｆ１１、２Ａ６治疗组分别有３０．０％、２０．０％小鼠长期存活；杂交细胞治疗组小鼠脾ＣＴＬ细胞杀伤ＳＰ２／０细胞活性显著高于对照组（Ｐ＜０．０５）。结果表明，１Ｆ１１和２Ａ６杂交细胞具有一定的体内抗肿瘤治疗作用。

By fusion of SP2/0 myeloma cells with LPS activated spleen B cells of BALB/C mice,we established several hybrid cell lines,and found that two of them,1F11,2A6,could enhance in vitro proliferation of PMA stimulated T lymphocytes.In model of tumor bearing mice,we observed effects of hybrid cells,1F11 and 2A6 on survival rate,spleen CTL cytotoxicity.Within 3 weeks,mice subcutaneously (SC) immunized with MMC killed 1F11 cells or 2A6 hybrid cells had 50.0% survival,in which 3/10 mice immunized with 1F11 cells and 2 of 10 mice immunized with 2A6 cells had a long term survival,while all of the control mice immunized sc with MMC killed SP2/0 died.Spleen CTL cytotoxicity of mice immunized with 1F11 and 2A6 cells was 54.0%±3.1%, 44.0% ± 3.5% respectively, which was higher than that of the control mice (21.0%±2.5%)( P <0.05).These results suggest that hybrid tumor cells 1F11 or 2A6 can effectively evoke tumor bearing mice immune response to SP2/0 myeloma and may be used as a new kind of tumor vaccine for tumor study.